Professor

Steven Lane

Email: 

Availability

Professor Steven Lane is:
Available for supervision

Search Professor Steven Lane’s works on UQ eSpace

179 works between 1977 and 2024
All (179) Journal Article (141) Conference Publication (38)

1 - 20 of 179 works

2024

Journal Article

Single Cell Genotype-Phenotype Analysis Demonstrates That Post-MPN AML Is Driven By Clonal Evolution and Loss of Transcriptional Heterogeneity within Stem Cell Compartments

Straube, Jasmin, Grabek, Julian, Cooper, Leanne, Haldar, Rohit, McNamara, Caroline, Ross, David M, Perkins, Andrew, Bywater, Megan and Lane, Steven W (2024). Single Cell Genotype-Phenotype Analysis Demonstrates That Post-MPN AML Is Driven By Clonal Evolution and Loss of Transcriptional Heterogeneity within Stem Cell Compartments. Blood, 144 (Supplement 1), 1346-1346. doi: 10.1182/blood-2024-199841

Single Cell Genotype-Phenotype Analysis Demonstrates That Post-MPN AML Is Driven By Clonal Evolution and Loss of Transcriptional Heterogeneity within Stem Cell Compartments

2024

Journal Article

Durable Responses Observed in Chronic Myelomonocytic Leukemia Treated with Lenzilumab and Azacitidine

Hiwase, Devendra, Ross, David M, Yeung, David T, Yong, Agnes S. M., Lane, Steven W, Brown, Anna, Fong, Chun Yew, Hughes, Timothy P, Reynolds, John and Thomas, Daniel (2024). Durable Responses Observed in Chronic Myelomonocytic Leukemia Treated with Lenzilumab and Azacitidine. Blood, 144 (Supplement 1), 1006-1006. doi: 10.1182/blood-2024-202867

Durable Responses Observed in Chronic Myelomonocytic Leukemia Treated with Lenzilumab and Azacitidine

2024

Journal Article

High Dose Ascorbate Reduces Interleukin-1 Beta Secretion in TET2 Mutant Monocytes and Demonstrates Excellent Safety and Tolerability in CMML Patients in Combination with Azacitidine

Kamel, Maha M, Robinson, Nirmal, Kutyna, Monika, Lim, Kelly, Thompson-Peach, Chloe, Lane, Steven W, Yeung, David T, Yong, Agnes S. M., Ross, David M, Hiwase, Devendra and Thomas, Daniel (2024). High Dose Ascorbate Reduces Interleukin-1 Beta Secretion in TET2 Mutant Monocytes and Demonstrates Excellent Safety and Tolerability in CMML Patients in Combination with Azacitidine. Blood, 144 (Supplement 1), 1817-1817. doi: 10.1182/blood-2024-204177

High Dose Ascorbate Reduces Interleukin-1 Beta Secretion in TET2 Mutant Monocytes and Demonstrates Excellent Safety and Tolerability in CMML Patients in Combination with Azacitidine

2024

Journal Article

Update of the Ascend-CML Study of Frontline Asciminib: High Rate of Optimal Response and Resistance Due to Mutations Is Rare

Yeung, David T, Shanmuganathan, Naranie, Yong, Agnes S. M., Shortt, Jake, Chee, Lynette C.Y., Vialla, Nicholas, Cunningham, Ilona, Ross, David M, D'Souza, Alwyn, Wright, Matthew P.F., Harrup, Rosemary, Forsyth, Cecily, Filshie, Robin, Lane, Steven W, Browett, Peter J., Grove, Carolyn S., Walia, Mannu, Branford, Susan, Reynolds, John, Grigg, Andrew P and Hughes, Timothy P (2024). Update of the Ascend-CML Study of Frontline Asciminib: High Rate of Optimal Response and Resistance Due to Mutations Is Rare. Blood, 144 (Supplement 1), 476-476. doi: 10.1182/blood-2024-201218

Update of the Ascend-CML Study of Frontline Asciminib: High Rate of Optimal Response and Resistance Due to Mutations Is Rare

2024

Journal Article

Overcoming Ven/Aza Resistance through Imetelstat-Mediated Lipophagy in Acute Myeloid Leukemia

Bruedigam, Claudia, Dulatre, Eunice Anne, Lee, Carol, Porter, Amy H, Lim, Elisa LSP, Shi, Alexander Z, Hodson, Mark P, Heidel, Florian H. and Lane, Steven W (2024). Overcoming Ven/Aza Resistance through Imetelstat-Mediated Lipophagy in Acute Myeloid Leukemia. Blood, 144 (Supplement 1), 52-52. doi: 10.1182/blood-2024-206473

Overcoming Ven/Aza Resistance through Imetelstat-Mediated Lipophagy in Acute Myeloid Leukemia

2024

Journal Article

<i>Dnmt3a</i> Mutation Promotes Expansion of a Quiescent Myeloid Progenitor Population in <i>Npm1c-Flt3ITD</i> Acute Myeloid Leukemia

Tavakoli, Paniz, Bywater, Megan, Straube, Jasmin, Ling, Victoria, Cooper, Emily, Haldar, Rohit, Janardhanan, Yashaswini, Cooper, Leanne, Bruedigam, Claudia, Grove, Carolyn S. and Lane, Steven W (2024). Dnmt3a Mutation Promotes Expansion of a Quiescent Myeloid Progenitor Population in Npm1c-Flt3ITD Acute Myeloid Leukemia. Blood, 144 (Supplement 1), 1347-1347. doi: 10.1182/blood-2024-201250

<i>Dnmt3a</i> Mutation Promotes Expansion of a Quiescent Myeloid Progenitor Population in <i>Npm1c-Flt3ITD</i> Acute Myeloid Leukemia

2024

Journal Article

CBL Variants in Chronic Myelomonocytic Leukemia Exhibit a Complex Sub-Clone Architecture with a High Frequency of RING Domain Mutations Sufficient to Induce GM-CSF Hypersensitivity

Lim, Kelly, Kutyna, Monika, Kan, Winnie, Lopez, Angel F., Brown, Anna, Yong, Agnes S. M., Lane, Steven W, Fong, Chun Yew, Hughes, Timothy P, Yeung, David T, Ross, David M, Hiwase, Devendra and Thomas, Daniel (2024). CBL Variants in Chronic Myelomonocytic Leukemia Exhibit a Complex Sub-Clone Architecture with a High Frequency of RING Domain Mutations Sufficient to Induce GM-CSF Hypersensitivity. Blood, 144 (Supplement 1), 3196-3196. doi: 10.1182/blood-2024-202682

CBL Variants in Chronic Myelomonocytic Leukemia Exhibit a Complex Sub-Clone Architecture with a High Frequency of RING Domain Mutations Sufficient to Induce GM-CSF Hypersensitivity

2024

Journal Article

CBL mutations in chronic myelomonocytic leukemia often occur in the RING domain with multiple subclones per patient: Implications for targeting

Lim, Kelly, Kan, Winnie L., Nair, Pramod C., Kutyna, Monika, Lopez, Angel F., Hercus, Timothy, Ross, David M., Lane, Steven, Fong, Chun Yew, Brown, Anna, Yong, Agnes, Yeung, David, Hughes, Timothy, Hiwase, Devendra and Thomas, Daniel (2024). CBL mutations in chronic myelomonocytic leukemia often occur in the RING domain with multiple subclones per patient: Implications for targeting. PLoS One, 19 (9 September) e0310641, 1-19. doi: 10.1371/journal.pone.0310641

CBL mutations in chronic myelomonocytic leukemia often occur in the RING domain with multiple subclones per patient: Implications for targeting

2024

Journal Article

Identifying disease-modifying potential in myelofibrosis clinical trials

Ross, David M, Lane, Steven W and Harrison, Claire N. (2024). Identifying disease-modifying potential in myelofibrosis clinical trials. Blood Journal, 144 (16), 1679-1688. doi: 10.1182/blood.2024024220

Identifying disease-modifying potential in myelofibrosis clinical trials

2024

Journal Article

Asciminib Monotherapy as Frontline Treatment of Chronic-Phase Chronic Myeloid Leukemia: Results from the ASCEND Study

Yeung, David T., Shanmuganathan, Naranie, Reynolds, John, Branford, Susan, Walia, Mannu, Yong, Agnes SM, Shortt, Jake, Chee, Lynette, Viiala, Nicholas, Cunningham, Ilona, Ross, David M, D'Souza, Alwyn Bernard, Wright, Matthew, Harrup, Rosemary Anne, Forsyth, Cecily Jane, Filshie, Robin, Lane, Steven W, Browett, Peter J, Grove, Carolyn S, Grigg, Andrew A and Hughes, Timothy P (2024). Asciminib Monotherapy as Frontline Treatment of Chronic-Phase Chronic Myeloid Leukemia: Results from the ASCEND Study. Blood Journal, 144 (19), 1993-2001. doi: 10.1182/blood.2024024657

Asciminib Monotherapy as Frontline Treatment of Chronic-Phase Chronic Myeloid Leukemia: Results from the ASCEND Study

2024

Conference Publication

3035 – INTERFERON ALPHA THERAPY ATTENUATES LEUKAEMIC TRANSFORMATION IN JAK2V617F-DRIVEN MPN WITH TRP53-LOSS

Bywater, Megan, Zhang, Ranran, Grabek, Julian, Halder, Rohit, Janardhanan, Yashaswini, Cooper, Leanne, Cooper, Emily, Ross, David, Straube, Jasmin and Lane, Steven (2024). 3035 – INTERFERON ALPHA THERAPY ATTENUATES LEUKAEMIC TRANSFORMATION IN JAK2V617F-DRIVEN MPN WITH TRP53-LOSS. EXPHEM 2024, Philadelphia, PA, United States: Elsevier BV. doi: 10.1016/j.exphem.2024.104357

3035 – INTERFERON ALPHA THERAPY ATTENUATES LEUKAEMIC TRANSFORMATION IN JAK2V617F-DRIVEN MPN WITH TRP53-LOSS

2024

Conference Publication

6471 Performance of eight different severity scores to predict critical care admission in paediatric inpatients treated for sepsis: a retrospective cohort study

Deef, Minnah, Bracken, Abbey, Lane, Steven, Gittings, Robert, Curran, Rachel, Foreman, Rachael, Gawne, Andrew, Carter, Bernie, Saron, Holly, Eyton-Chong, Chin-Kien, Mehta, Fulya, Siner, Sarah, Lambert, Caroline, Sefton, Gerri and Carrol, Enitan D (2024). 6471 Performance of eight different severity scores to predict critical care admission in paediatric inpatients treated for sepsis: a retrospective cohort study. BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health. doi: 10.1136/archdischild-2024-rcpch.491

6471 Performance of eight different severity scores to predict critical care admission in paediatric inpatients treated for sepsis: a retrospective cohort study

2024

Journal Article

Microclots, as defined by amyloid-fibrinogen aggregates, predict risks of disseminated intravascular coagulation and mortality

Scho, Jeremy, Abrams, Simon T., Jenkins, Rosalind, Lane, Steven, Wang, Guozheng and Toh, Cheng-Hock (2024). Microclots, as defined by amyloid-fibrinogen aggregates, predict risks of disseminated intravascular coagulation and mortality. Blood Advances, 8 (10), 2499-2508. doi: 10.1182/bloodadvances.2023012473

Microclots, as defined by amyloid-fibrinogen aggregates, predict risks of disseminated intravascular coagulation and mortality

2024

Journal Article

Autophagy prevents graft failure during murine Graft versus Host Disease

Lineburg, Katie E., Leveque-El Mouttie, Lucie, Hunter, Christopher R., Le Texier, Laeitia, McGirr, Crystal, Teal, Bianca, Blazar, Bruce R., Lane, Steven W., Hill, Geoffrey R., Levesque, Jean-Pierre and MacDonald, Kelli P.A. (2024). Autophagy prevents graft failure during murine Graft versus Host Disease. Blood Advances, 8 (8), 2032-2043. doi: 10.1182/bloodadvances.2023010972

Autophagy prevents graft failure during murine Graft versus Host Disease

2024

Journal Article

Survival for the fittest: guadecitabine in rel/ref AML

Sheehy, Joshua and Lane, Steven W. (2024). Survival for the fittest: guadecitabine in rel/ref AML. Blood Advances, 8 (8), 2018-2019. doi: 10.1182/bloodadvances.2024012569

Survival for the fittest: guadecitabine in rel/ref AML

2024

Journal Article

Low iodine nutrition knowledge in Chinese breastfeeding women despite adequate iodine status

Liu, Shuchang, Sharp, Andrew, Lane, Steven, Villanueva, Elmer V., Lu, Zhiliang and Ma, Zheng Feei (2024). Low iodine nutrition knowledge in Chinese breastfeeding women despite adequate iodine status. Nutrients, 16 (4) 491, 1-14. doi: 10.3390/nu16040491

Low iodine nutrition knowledge in Chinese breastfeeding women despite adequate iodine status

2024

Journal Article

Australia and New Zealand consensus position statement: use of COVID-19 therapeutics in patients with haematological malignancies

Campbell, Ashlea, Teh, Benjamin, Mulligan, Stephen, Ross, David M., Weinkove, Robert, Gilroy, Nicole, Gangatharan, Shane, Prince, Henry Miles, Szer, Jeff, Trotman, Judith, Lane, Steven, Dickinson, Michael, Quach, Hang, Enjeti, Anoop K., Ku, Matthew, Gregory, Gareth, Hapgood, Gregory, Ho, Phoebe Joy, Cochrane, Tara, Cheah, Chan, Greenwood, Matthew, Latimer, Maya, Berkahn, Leanne, Wight, Joel, Armytage, Tasman, Diamond, Peter, Tam, Constantine S. and Hamad, Nada (2024). Australia and New Zealand consensus position statement: use of COVID-19 therapeutics in patients with haematological malignancies. Internal Medicine Journal, 54 (2), 328-336. doi: 10.1111/imj.16303

Australia and New Zealand consensus position statement: use of COVID-19 therapeutics in patients with haematological malignancies

2024

Journal Article

Imetelstat-mediated alterations in fatty acid metabolism to induce ferroptosis as a therapeutic strategy for acute myeloid leukemia

Bruedigam, Claudia, Porter, Amy H., Song, Axia, Vroeg in de Wei, Gerjanne, Stoll, Thomas, Straube, Jasmin, Cooper, Leanne, Cheng, Guidan, Kahl, Vivian F. S., Sobinoff, Alexander P., Ling, Victoria Y., Jebaraj, Billy Michael Chelliah, Janardhanan, Yashaswini, Haldar, Rohit, Bray, Laura J., Bullinger, Lars, Heidel, Florian H., Kennedy, Glen A., Hill, Michelle M., Pickett, Hilda A., Abdel-Wahab, Omar, Hartel, Gunter and Lane, Steven W. (2024). Imetelstat-mediated alterations in fatty acid metabolism to induce ferroptosis as a therapeutic strategy for acute myeloid leukemia. Nature Cancer, 5 (1), 47-65. doi: 10.1038/s43018-023-00653-5

Imetelstat-mediated alterations in fatty acid metabolism to induce ferroptosis as a therapeutic strategy for acute myeloid leukemia

2024

Journal Article

A randomised double-blind placebo-controlled trial of minocycline and/or omega-3 fatty acids added to treatment as usual for at risk Mental States: The NAYAB study

Qurashi, Inti, Chaudhry, Imran B., Khoso, Ameer B., Husain, Muhammad Omair, Hafeez, Danish, Kiran, Tayyeba, Lane, Steven, Naqvi, Haider A., Minhas, Fareed A., Nizami, Asad Tamizuddin, Razzaque, Bushra, Bokhari, Sumira Qambar, Yung, Alison R., Deakin, Bill and Husain, Nusrat (2024). A randomised double-blind placebo-controlled trial of minocycline and/or omega-3 fatty acids added to treatment as usual for at risk Mental States: The NAYAB study. Brain Behavior and Immunity, 115, 609-616. doi: 10.1016/j.bbi.2023.10.025

A randomised double-blind placebo-controlled trial of minocycline and/or omega-3 fatty acids added to treatment as usual for at risk Mental States: The NAYAB study

2023

Journal Article

Immunoproteasome function maintains oncogenic gene expression in KMT2A-complex driven leukemia

Tubio-Santamaria, Nuria, Jayavelu, Ashok Kumar, Schnoeder, Tina M., Eifert, Theresa, Hsu, Chen-Jen, Perner, Florian, Zhang, Qirui, Wenge, Daniela V., Hansen, Fynn M., Kirkpatrick, Joanna M., Jyotsana, Nidhi, Lane, Steven W., von Eyss, Bjoern, Deshpande, Aniruddha J., Kuehn, Michael W. M., Schwaller, Juerg, Cammann, Clemens, Seifert, Ulrike, Ebstein, Frederic, Krueger, Elke, Hochhaus, Andreas, Heuser, Michael, Ori, Alessandro, Mann, Matthias, Armstrong, Scott A. and Heidel, Florian H. (2023). Immunoproteasome function maintains oncogenic gene expression in KMT2A-complex driven leukemia. Molecular Cancer, 22 (1) 196. doi: 10.1186/s12943-023-01907-7

Immunoproteasome function maintains oncogenic gene expression in KMT2A-complex driven leukemia

Availability

Professor Steven Lane is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Supervision history

Current supervision

  • Doctor Philosophy

    Genomic drivers of progression of MPN to AML

    Principal Advisor

  • Doctor Philosophy

    Leukemic transformation STEMming from myeloproliferative neoplasm: Resolving the loss of stem cell heterogeneity

    Principal Advisor

  • Doctor Philosophy

    Targeting the cancer-immune cross talk in Acute Myeloid Leukaemia

    Associate Advisor

Completed supervision

Enquiries

For media enquiries about Professor Steven Lane's areas of expertise, story ideas and help finding experts, contact our Media team:

communications@uq.edu.au